Neurodevelopmental Outcome after Hematopoietic Cell Transplantation in Inborn Errors of Metabolism: Current Considerations and Future Perspectives

Abstract

Inborn errors of metabolism (IEM) comprise an assorted group of inherited diseases, some of which are due to disordered lysosomal or peroxisomal function and some of which might be improved following hematopoietic cell transplantation (HCT). In these disorders the onset in infancy or early childhood is typically accompanied by rapid deterioration, resulting in early death in the more severe phenotypes. Timely diagnosis and immediate referral to an IEM specialist are essential steps in optimal management. Treatment recommendations are based on the diagnosis, its phenotype, rate of progression, prior extent of disease, family values, and expectations, and the risks and benefits associated with available therapies, including HCT. International collaborative efforts are of utmost importance in determining outcomes of therapy for these rare diseases, and have improved those outcomes significantly over the last decades. In this review, we will focus on the neurodevelopmental outcomes after HCT in IEM, providing an international perspective on progress, limitations, and future directions.

Keywords

hematopoietic cell transplantation - neurodevelopment - indications - gene therapy

• References

• 1 Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968; 162 (3853) 570-572
• 2 Hobbs JR, Hugh-Jones K, Barrett AJ , et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981; 2 (8249) 709-712
• 3 Boelens JJ, Aldenhoven M, Purtill D , et al; Eurocord; Inborn Errors Working Party of European Blood and Marrow Transplant group; Duke University Blood and Marrow Transplantation Program; Centre for International Blood and Marrow Research. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 2013; 121 (19) 3981-3987
• 4 Aldenhoven M, Wynn RF, Orchard PJ , et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 2015; 125 (13) 2164-2172
• 5 Aldenhoven M, Jones SA, Bonney D , et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant 2015; 21 (6) 1106-1109
• 6 Miller WP, Rothman SM, Nascene D , et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood 2011; 118 (7) 1971-1978
• 7 Wynn RF, Wraith JE, Mercer J , et al. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr 2009; 154 (4) 609-611
• 8 Escolar ML, Poe MD, Provenzale JM , et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352 (20) 2069-2081
• 9 Boelens JJ, Orchard PJ, Wynn RF. Transplantation in inborn errors of metabolism: current considerations and future perspectives. Br J Haematol 2014; 167 (3) 293-303
• 10 Martin HR, Poe MD, Provenzale JM, Kurtzberg J, Mendizabal A, Escolar ML. Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. Biol Blood Marrow Transplant 2013; 19 (4) 616-624
• 11 Biffi A, Montini E, Lorioli L , et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341 (6148) 1233158
• 12 Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 1976; 26 (4) 851-860
• 13 Schaumburg HH, Powers JM, Raine CS , et al. Adrenoleukodystrophy: a clinical, pathological and biochemical study. Adv Exp Med Biol 1976; 68: 379-387
• 14 Moser HW. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 1995; 54 (5) 740-745
• 15 Moser HW, Bergin A, Naidu S, Ladenson PW. Adrenoleukodystrophy. Endocrinol Metab Clin North Am 1991; 20 (2) 297-318
• 16 Aubourg P, Blanche S, Jambaqué I , et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990; 322 (26) 1860-1866
• 17 Loes DJ, Stillman AE, Hite S , et al. Childhood cerebral form of adrenoleukodystrophy: short-term effect of bone marrow transplantation on brain MR observations. AJNR Am J Neuroradiol 1994; 15 (9) 1767-1771
• 18 Loes DJ, Fatemi A, Melhem ER , et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 2003; 61 (3) 369-374
• 19 Cartier N, Hacein-Bey-Abina S, Bartholomae CC , et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326 (5954) 818-823
• 20 Aldenhoven M, Boelens JJ, de Koning TJ. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 2008; 14 (5) 485-498
• 21 Staba SL, Escolar ML, Poe M , et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004; 350 (19) 1960-1969
• 22 Boelens JJ, Wynn RF, O'Meara A , et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007; 40 (3) 225-233
• 23 Boelens JJ, Bierings M, Wynn RF. HSCT for inborn errors of metabolism. In: Apperley J, Carreras E, Gluckman E, Masszi T, eds. The 2012 Revised Edition of the EBMT-ESH Handbook on Haematopoietic Stem Cell Transplantation. Chap 20. EBMT-ESH. 2012: 558-571
• 24 Bartelink IH, van Reij EML, Gerhardt CE , et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant 2014; 20 (3) 345-353
• 25 Bartelink IH, Boelens JJ, Bredius RGM , et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet 2012; 51 (5) 331-345
• 26 Langereis EJ, Borgo A, Crushell E , et al. Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure. Orphanet J Rare Dis 2013; 8 (1) 155